Form 8-K

8-K — NEUROONE MEDICAL TECHNOLOGIES Corp

Accession: 0001213900-26-054744

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001500198

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0290094-8k_neuroone.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED MAY 12, 2026 (ea029009401ex99-1.htm)

GRAPHIC (ea029009401ex99-1_img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0290094-8k_neuroone.htm · Sequence: 1

false

0001500198

2026-05-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 12, 2026

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip

code)

952-426-1383

(Registrant’s telephone number including

area code)

(Registrant’s former name or former address,

if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NMTC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2026, NeuroOne Medical Technologies

Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31,

2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”)

and is incorporated herein by reference.

In accordance with General Instruction B.2. of

Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item

2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s

filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of

any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated May 12, 2026

104

Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

Dated: May 12, 2026

By:

/s/ David Rosa

David Rosa

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED MAY 12, 2026

EX-99.1

Filename: ea029009401ex99-1.htm · Sequence: 2

Exhibit 99.1

NeuroOne Reports Fiscal

Q2 2026 Financial Results and Provides Corporate Business Update

Product Revenue of

$2.4 Million up 72% Year Over Year

Successfully Completed

16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free*

Management to Host

Conference Call Today at 8:30 a.m. Eastern Time

EDEN PRAIRIE, Minn., May 12, 2026 -- NeuroOne

Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated

to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for

the second quarter of fiscal year 2026 ended March 31, 2026.

Company Highlights

● Product revenue was $2.4M for the quarter, a

72% increase versus product revenue of $1.4 million in the second quarter of fiscal 2025.

● To date, the Company successfully completed 16

cases using the OneRF® Trigeminal Nerve Ablation System for the treatment of facial pain known as trigeminal neuralgia, with all patients

reportedly pain free after the procedure.*

● A new high-net-worth investor acquired approximately

7.4% of NeuroOne's outstanding common stock in the open market.

● David Wambeke appointed Chief Business Officer

to lead NeuroOne’s drug delivery program, oversee investor relations, and support business development. Mr. Wambeke also purchased

1,000,000 shares of NeuroOne common stock, pre-split.

● Targeted commercial availability of the Company’s

drug delivery system in the second half of fiscal 2026 for use in investigational clinical studies or animal studies, with final product

builds underway.

● Successfully regained Nasdaq compliance

with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and the matter is closed.

● Announced a collaboration with the Department

of Neurology’s Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating next-generation

epilepsy therapies using NeuroOne’s sEEG-based platform.

● Peer-reviewed case series was published supporting

the use of NeuroOne’s FDA-cleared OneRF Ablation System in existing stereotactic workflows, with bedside treatment capability and

reported reductions in seizure burden in drug-resistant epilepsy patients.*

● Launched strategic initiative to secure a second

manufacturing source, strengthening the Company’s supply chain and expanding capacity to meet increased demand of future product

introductions.

● Completed the stage 2 audit of the Company’s

Minnesota facility, advancing toward ISO 13485 certification. If received, ISO certification, combined with the necessary regulatory approvals

in target geographies, is expected to enable international distribution of NeuroOne’s products.

● Completed user design requirements for the basivertebral

nerve ablation system; initiating animal studies to support continued development of the program.

● Presented at the North American Neuromodulation

Society and the American Association of Neurological Surgeons.

Management Commentary

“This was a very productive quarter for

NeuroOne. Product revenue grew 72% year-over-year, we continued to gain clinical experience with our OneRF Trigeminal Neuralgia Ablation

System and have completed 16 procedures to date with all patients reportedly pain free. We continue to be optimistic regarding the advantages

and clinical performance of the device for treating facial pain. We also had a peer-reviewed clinical publication validate what physicians

using our platform have been telling us – that real-time temperature monitoring during sEEG-guided RF ablation is a meaningful clinical

advantage for patients with drug resistant epilepsy.

“At the same time, we executed on

the strategic priorities we laid out at the start of the year. We completed our stage 2 ISO 13485 audit, paving the way for international

expansion. We regained Nasdaq compliance, restructured our capital base through the reverse stock split, and added a highly experienced

executive - David Wambeke, as Chief Business Officer. Also, effective July 1, Christopher Volker will assume the role as our next Chief

Financial Officer. Together, these moves will help to lead our next phase of growth.

“Looking ahead, the catalysts are clear:

continued expansion of our OneRF Brain Ablation and Trigeminal Neuralgia Ablation Systems, commercial launch of our drug delivery system

in the second half of fiscal 2026 for use in investigational clinical studies or animal studies, continued progress in basivertebral nerve

ablation and spinal cord stimulation, and an expanding international footprint as we make progress towards ISO 13485 certification. We

are well-positioned for the future and I’m proud of what this team has built.” concluded Dave Rosa, CEO of NeuroOne.

Operational Highlights and Updates

OneRF® Trigeminal Nerve

Ablation System:

● Successfully completed sixteen cases to-date

using the OneRF Trigeminal Nerve Ablation System, with all patients reportedly pain free.*

● Company was highlighted in The Business Research

Company 4/24/26 report, which stated that emerging growth patterns are driving expansion in the trigeminal neuralgia market (valued at

$780 million) to stereotactic surgery using technology similar to the OneRF Trigeminal Neuralgia Ablation System.

sEEG-Based Drug Delivery Program:

● Documentation and final device builds in process

to ensure availability for use in investigational clinical studies or animals in fiscal 2026.

● Working with the University of Minnesota to provide

devices for animal and human IDE studies.

● Focused on glioblastomas (brain tumors), gene

and cell-based therapies for brain related disorders.

● Evaluating distributors for commercial distribution.

Basi-Vertebral Nerve Ablation

● Completed user requirements for the Basi-vertebral

nerve ablation system.

● Strategy remains to leverage OneRF®

generator, temperature probe, and ablation electrode while outsourcing access tools either through outside vendors or potential distribution

partners.

● Pre-clinical testing initiated.

OneRF® Ablation System in the

Brain:

● Successfully completed stage 2 audit on ISO 13485

certification for Outside the U.S. (“OUS”) distribution and remain bullish on certification in latter part of 2026. This will

allow us to ship product outside the US into geographies that recognize FDA clearance.

● Pipeline of centers waiting for hospital approval

to begin trialing the system.

● Developing webinar to gain additional exposure

with neurologists and neurosurgeons that will highlight clinical experience with the device along with patient interview.

● Reported clinical outcomes remain positive with

respect to reduction or elimination in patient seizures.

● The OneRF brain ablation system was highlighted

at Zimmer Biomet’s booth at the recent AANS meeting in San Antonio, Texas as well as in presentations on the technology.

Spinal Cord Stimulation (SCS) Percutaneous

Paddle Lead Program:

● Concluded chronic animal study and will implement

changes based on study results.

● System was displayed at the NANS annual meeting.

Second Quarter Fiscal 2026 Financial Results

Product revenue was $2.4 million in the second

quarter of fiscal 2026, a 72% increase compared to product revenue of $1.4 million in the second quarter of fiscal 2025. The increase

was driven by higher sales of OneRF Products. For the six months ended March 31, 2026, product revenue was $5.3 million, an increase of

13% compared to $4.7 million in the same period of the prior fiscal year. The Company had no license revenue in the second quarter or

first six months of fiscal 2026, compared to license revenue of $3.0 million in the first six months of fiscal 2025, which was derived

from the expanded exclusive distribution agreement with Zimmer.

Product gross profit was $1.3 million, or 53.8%

of product revenue, in the second quarter of fiscal 2026, compared to product gross profit of $0.8 million, or 55.6% of product revenue,

in the same quarter of the prior fiscal year. For the six months ended March 31, 2026, product gross profit was $2.9 million, or 54.0%

of product revenue, compared to $2.7 million, or 57.9% of product revenue, in the same period of the prior fiscal year.

Total operating expenses were $3.4 million in

the second quarter of fiscal 2026, compared to $3.5 million in the same quarter of the prior year. Research & Development (R&D)

expense in the second quarter of fiscal 2026 was $1.5 million, compared to $1.5 million in the same quarter of the prior year. Selling,

General & Administrative (SG&A) expense in the second quarter of fiscal 2026 was $1.9 million, compared to $1.9 million in the

same quarter of the prior year. For the first six months of fiscal 2026, total operating expenses were $6.7 million, compared to $6.7 million in

the same period of fiscal 2025. R&D expense in the first six months of fiscal 2026 were $2.9 million, compared to $2.7

million in the same period of fiscal 2025. SG&A expense in the first six months of fiscal 2026 decreased 4% to $3.8 million, compared

to $4.0 million in the prior year period.

Net loss in the second quarter of fiscal 2026

was $2.1 million, or ($0.25) per basic and diluted share, compared to net loss of $2.3 million, or ($0.44) per basic and diluted share,

in the same quarter of the prior year. The net loss in the second quarter of fiscal 2025 was favorably impacted by a $0.4 million gain

from the fair value change in the warrant liability. For the six months ended March 31, 2026, net loss was $3.5 million, or ($0.42) per

basic share and ($0.44) per diluted share, compared to net loss of $0.5 million, or ($0.09) per basic and diluted share, in the same period

of the prior year. The lower net loss in the first six months of fiscal 2025 reflected $3.0 million of license revenue recognized in the

first quarter of fiscal 2025.

As of March 31, 2026, the Company had cash and

cash equivalents of $2.8 million, compared to $6.6 million as of September 30, 2025. The Company also had $2.4 million in accounts receivable

as of March 31, 2026, which should be converted to cash in the third quarter of fiscal 2026 based on normal collection patterns.

The Company had working capital of $5.7 million

as of March 31, 2026, compared to working capital of $7.9 million as of September 30, 2025. The Company had no debt outstanding as of

March 31, 2026.

Conference Call and Webcast

Management will host an investor conference call

and webcast today, Tuesday, May 12, 2026, at 8:30 a.m. Eastern time to discuss the Company’s fiscal second quarter 2026 financial

results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Date: Tuesday, May 12, 2026

Time: 8:30 a.m. Eastern time

U.S. Dial-In (Toll Free): 888-506-0062

International Dial-In: 973-528-0011

Participant Access Code: 224785

Webcast:

https://www.webcaster5.com/Webcast/Page/2821/53948

Please join at least five minutes before the start of the call to ensure

timely participation.

A playback of the call will be available through Tuesday, May 26, 2026.

To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay

passcode 53948. A webcast replay will also be available using the webcast link above through Wednesday, May 12, 2027.

About NeuroOne

NeuroOne Medical Technologies Corporation is a

medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.

NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families:

Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation

System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve

patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery,

basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward looking

statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other

factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information

expressed or implied by these forward-looking statements. In some cases, you can identify forward looking statements by the words or phrases

"may," "might," "will," "could," "would," "should," "expect," "intend,"

"plan," "forecasts," "objective," "anticipate," "believe," "estimate," "predict,"

"project," "potential," "target," "seek," "contemplate," "continue, "focused

on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to

identify statements about the future. Forward looking statements may include statements regarding the potential sales of the sEEG-Based

Drug Delivery system in investigational clinical studies or animals in Q3 fiscal 2026, the collaborations with the University of Minnesota

and other companies, our ability to obtain ISO 13485 or other regulatory approvals and expand internationally, the collection of accounts

receivables, our ability to expand the sales of our OneRF Trigeminal Nerve Ablation System, our and the Company’s ability to expand

revenue. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements

are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks

related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic

partnerships may not facilitate the commercialization or market acceptance of our technology whether due to supply chain disruptions,

labor shortages or otherwise risks that our technology will not perform as expected based on results of our pre-clinical and clinical

trials risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability

to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology

uncertainties inherent in the development process of our technology risks related to changes in regulatory requirements or decisions of

regulatory authorities that we may not have accurately estimated the size and growth potential of the markets for our technology risks

related to clinical trial patient enrollment and the results of clinical trials that we may be unable to protect our intellectual property

rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings

with the Securities and Exchange Commission. These forward looking statements speak only as of the date of this press release and NeuroOne

undertakes no obligation to revise or update any forward looking statements for any reason, even if new information becomes available

in the future.

Caution: Federal law restricts this device to sale by or on the order

of a physician.

* Disclaimer: This recounts several patients’ experiences

and may not be representative of all patient outcomes.

IR Contact

MZ Group – MZ North America

NMTC@mzgroup.us

NeuroOne Medical Technologies Corporation

Condensed Balance Sheets

(Unaudited)

As of

March 31,

September 30,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$ 2,804,011

$ 6,570,382

Accounts receivable

2,426,518

1,264,805

Inventory, net

1,866,633

2,226,805

Deferred offering costs

22,920

Prepaid expenses

283,716

141,372

Total current assets

7,403,798

10,226,284

Intangible assets, net

33,789

44,946

Right-of-use asset

196,775

255,195

Property and equipment, net

230,596

259,222

Total assets

$ 7,864,958

$ 10,785,647

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$ 934,196

$ 1,010,369

Accrued expenses and other liabilities

755,258

1,292,714

Total current liabilities

1,689,454

2,303,083

Warrant liability

709,507

1,266,894

Operating lease liability, long term

92,361

143,148

Total liabilities

2,491,322

3,713,125

Commitments and contingencies (Note 4)

Stockholders’ equity:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.

—

Common stock, $0.001 par value; 100,000,000 shares authorized; 8,615,532 and 8,334,336 shares issued and outstanding as of March 31, 2026 and September 30, 2025, respectively.

8,616

8,334

Additional paid–in capital

87,498,366

85,673,975

Accumulated deficit

(82,133,346 )

(78,609,787 )

Total stockholders’ equity

5,373,636

7,072,522

Total liabilities and stockholders’ equity

$ 7,864,958

$ 10,785,647

NeuroOne Medical Technologies Corporation

Condensed Statements of Operations

(unaudited)

For the

Three Months Ended

For the

Six Months Ended

March 31,

2026

2025

2026

2025

Product revenue

$ 2,391,185

$ 1,386,550

$ 5,283,820

$ 4,660,717

Cost of product revenue

1,104,568

615,489

2,429,375

1,962,767

Product gross profit

1,286,617

771,061

2,854,445

2,697,950

License revenue

—

3,000,000

Operating expenses:

Selling, general and administrative

1,919,371

1,940,414

3,804,826

3,983,868

Research and development

1,468,090

1,510,663

2,857,770

2,682,891

Total operating expenses

3,387,461

3,451,077

6,662,596

6,666,759

Loss from operations

(2,100,844 )

(2,680,016 )

(3,808,151 )

(968,809 )

Fair value change in warrant liability

(8,271 )

390,351

214,469

779,796

Financing costs

—

(324,738 )

Other income

23,446

19,058

70,123

28,466

Loss before income taxes

(2,085,669 )

(2,270,607 )

(3,523,559 )

(485,285 )

Provision for income taxes

—

Net loss

$ (2,085,669 )

$ (2,270,607 )

$ (3,523,559 )

$ (485,285 )

Net loss per share (Note 1):

Basic

$ (0.25 )

$ (0.44 )

$ (0.42 )

$ (0.09 )

Diluted

$ (0.25 )

$ (0.44 )

$ (0.09 )

Number of shares used in per share calculations (Note 1):

Basic

8,484,926

5,185,075

8,436,158

5,161,971

Diluted

8,484,926

5,185,075

8,554,213

5,161,971

GRAPHIC

Filename: ea029009401ex99-1_img1.jpg · Sequence: 3

Binary file (2768 bytes)

Download ea029009401ex99-1_img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 12, 2026

Entity File Number

001-40439

Entity Registrant Name

NeuroOne Medical Technologies Corporation

Entity Central Index Key

0001500198

Entity Tax Identification Number

27-0863354

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7599 Anagram Dr.

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

426-1383

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

NMTC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration